Literature DB >> 17883431

Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases.

M Fox1, R Sweis, T Wong, A Anggiansah.   

Abstract

Oesophageal spasm presents with dysphagia and chest pain. Current treatments are limited by poor efficacy and side effects. Studies in health and oesophageal dysmotility show that sildenafil reduces peristaltic pressure and velocity; however the clinical efficacy and tolerability in symptomatic oesophageal spasm remains uncertain. We provided open-label sildenafil treatment to two patients with severe, treatment resistant symptoms associated with oesophageal spasm. The effects of sildenafil on oesophageal function and symptoms were documented by high resolution manometry (HRM). Patients were followed up to assess the efficacy of maintenance treatment with sildenafil b.i.d. HRM revealed focal and diffuse spasm in the smooth muscle oesophagus that were associated with symptoms in both cases, especially on swallowing solids. Lower oesophageal sphincter function was normal. A therapeutic trial of 25-50 mg sildenafil suppressed oesophageal contraction almost completely for water swallows; however effective, coordinated peristalsis returned with reduced frequency of spasm for solid swallows. Dysphagia and chest pain resolved during the therapeutic trial and efficacy was maintained on maintenance treatment with 25-50 mg sildenafil b.i.d. without troublesome side effects. This report shows that sildenafil can improve oesophageal function and relieve dysphagia and chest pain in patients with oesophageal spasm in whom other treatments have failed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17883431     DOI: 10.1111/j.1365-2982.2007.00957.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  9 in total

Review 1.  Therapeutic options in oesophageal dysphagia.

Authors:  Jan Tack; Giovanni Zaninotto
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-31       Impact factor: 46.802

2.  Distal esophageal spasm with multiple esophageal diverticula successfully treated by peroral endoscopic myotomy.

Authors:  Koji Otani; Shinwa Tanaka; Fumiaki Kawara; Junichi Fujikawa; Akinari Sawada; Risa Uemura; Tetsuya Tanigawa; Toshio Watanabe; Takeshi Azuma; Yasuhiro Fujiwara
Journal:  Clin J Gastroenterol       Date:  2017-07-29

Review 3.  Esophageal hypomotility and spastic motor disorders: current diagnosis and treatment.

Authors:  Miguel A Valdovinos; Monica R Zavala-Solares; Enrique Coss-Adame
Journal:  Curr Gastroenterol Rep       Date:  2014-11

Review 4.  Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics.

Authors:  Dhyanesh A Patel; Rena Yadlapati; Michael F Vaezi
Journal:  Gastroenterology       Date:  2022-02-25       Impact factor: 33.883

Review 5.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

Review 6.  The Relevance of Spastic Esophageal Disorders as a Diagnostic Category.

Authors:  Michelle P Clermont; Nitin K Ahuja
Journal:  Curr Gastroenterol Rep       Date:  2018-08-06

7.  Examination of the effects of vardenafil on esophageal function using multichannel intraluminal impedance and manometry.

Authors:  Tae Hee Lee; Joon Seong Lee; Su Jin Hong; Seong Ran Jeon; Wan Jung Kim; Hyun Gun Kim; Joo Young Cho; Jin-Oh Kim
Journal:  J Neurogastroenterol Motil       Date:  2012-10-09       Impact factor: 4.924

Review 8.  Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.

Authors:  Michael Camilleri
Journal:  J Clin Invest       Date:  2013-10-01       Impact factor: 14.808

9.  Sildenafil normalizes bowel transit in preclinical models of constipation.

Authors:  Sarah K Sharman; Bianca N Islam; Yali Hou; Margaux Usry; Allison Bridges; Nagendra Singh; Subbaramiah Sridhar; Satish Rao; Darren D Browning
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.